|Home | About | Journals | Submit | Contact Us | Français|
Although the proposal for a dissociative subtype of posttraumatic stress disorder (PTSD) in DSM-5 is supported by considerable clinical and neurobiological evidence, this evidence comes mostly from referred samples in Western countries. Cross-national population epidemiologic surveys were analyzed to evaluate generalizability of the subtype in more diverse samples.
Interviews were administered to 25,018 respondents in 16 countries in the World Health Organization World Mental Health Surveys. The Composite International Diagnostic Interview was used to assess 12-month DSM-IV PTSD and other common DSM-IV disorders. Items from a checklist of past-month nonspecific psychological distress were used to assess dissociative symptoms of depersonalization and derealization. Differences between PTSD with and without these dissociative symptoms were examined across a variety of domains, including index trauma characteristics, prior trauma history, childhood adversity, sociodemographic characteristics, psychiatric comorbidity, functional impairment, and treatment seeking.
Dissociative symptoms were present in 14.4% of respondents with 12-month DSM-IV/Composite International Diagnostic Interview PTSD and did not differ between high and low/middle income countries. Symptoms of dissociation in PTSD were associated with high counts of re-experiencing symptoms and net of these symptom counts with male sex, childhood onset of PTSD, high exposure to prior (to the onset of PTSD) traumatic events and childhood adversities, prior histories of separation anxiety disorder and specific phobia, severe role impairment, and suicidality.
These results provide community epidemiologic data documenting the value of the dissociative subtype in distinguishing a meaningful proportion of severe and impairing cases of PTSD that have distinct correlates across a diverse set of countries.
For over a century, clinicians have observed a wide range of dissociative phenomena in trauma survivors, such as affect compartmentalization, disrupted memory encoding, and time distortion and fugue (1,2). Yet, only two dissociative symptoms, flashbacks and psychogenic amnesia, are included in the DSM-IV diagnostic criteria for posttraumatic stress disorder (PTSD) (3). A proposal has been made to include a dissociative subtype of PTSD in the forthcoming DSM-5 revision (http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=165). One important basis for this proposal is concern that some PTSD patients experience dissociative symptoms not in DSM-IV, which, if recognized, could improve appropriate diagnosis and treatment (4–7). Another important basis for the proposal is the observation that some people with PTSD respond to trauma with a range of dissociative symptoms of which the hallmark symptoms are derealization and depersonalization (8). Empirical support for the subtype includes evidence for antecedent validators (that trauma and stress are linked to dissociation) (4), concurrent validators (that distinctive psychobiological mechanisms underlie dissociation) (9), predictive validators (that dissociation predicts poor treatment outcome) (10,11), and differential response to treatments tailored to this subtype (12,13).
Existing studies of this dissociative subtype, however, are mainly based on treatment-seeking samples in Western countries (5–7,9,12,14–17). As treatment seekers exhibit greater comorbidity and impairment than nontreatment seekers, clinical samples do not represent the full spectrum of PTSD in the population. Indeed, dissociation may prove especially sensitive to treatment selection bias, given that symptoms such as reduced awareness, fragmented memories, and compartmentalized affects could influence help seeking. To our knowledge, though, there have been no large-scale population-based studies of dissociation in PTSD, leaving it unclear whether associations documented in clinical studies, such as those between the dissociative subtype and early childhood adversities or repeated traumatic experiences (9,18,19), generalize to the population. Dissociation may also prove highly sensitive to culture bias, making it important to consider the possibility of cross-cultural variability in symptom expression and meaning (20,21).
The current report uses epidemiologic data from 16 countries in the World Health Organization (WHO) World Mental Health (WMH) Surveys to examine the generalizability of previously reported results regarding the prevalence and correlates of PTSD with versus without dissociation. We focus on both predictors (characteristics of the trauma implicated in the PTSD, socio-demographics, childhood adversities, prior traumas, temporally primary comorbid disorders) and outcomes (PTSD symptom counts, role impairments, suicidality, treatment) that we have reason to believe, based on previous studies (4,7,9,14–18), might distinguish between PTSD with and without dissociation.
Interviews were administered in nine countries classified by the World Bank (22) as high income (Belgium, France, Germany, Italy, Japan, Northern Ireland, Portugal, Spain, United States) and seven upper-middle income (São Paulo in Brazil, Bulgaria, Lebanon, Mexico, Romania) or low/lower-middle income (Colombia and Beijing/Shanghai in the People’s Republic of China). All but five surveys were based on area probability household samples representative of the entire nation. The exceptions were surveys of all urbanized areas in two countries (Colombia and Mexico) and of specific metropolitan areas in three countries (São Paulo in Brazil, a series of cities in Japan, and Beijing and Shanghai in the People’s Republic of China). Interviews were conducted face-to-face in respondent homes after obtaining informed consent. Human Subjects Committees monitored the surveys and approved recruitment and consent procedures in each country.
Interviews had two parts. Part I, administered to all respondents, assessed core anxiety, mood, disruptive behavior, and substance disorders and basic sociodemographic correlates. All part I respondents with a lifetime history of any core disorder plus a probability subsample of other respondents were administered part II, which assessed other disorders and a wide range of correlates. Trauma and PTSD were assessed in part II. Probability subsamples of part II respondents were administered exploratory question series, one of which assessed 30-day nonspecific psychological distress and included questions about dissociation that can be used to define a dissociative subtype of PTSD. This subset of part II respondents is the focus of the current report. This subsample was weighted to adjust for the undersampling of part I noncases and to adjust for sociodemographic/geographic discrepancies between samples and populations based on census data. The number of part II respondents in this subsample ranges from 189 across five Western European countries (Belgium, France, Germany, Italy, and Spain) to 5692 in the United States and totals 25,018 across all countries. Response rates range from a low of 55.1% (Japan) to 87.7% (Colombia) (69.0% weighted average). Technical details about WMH sample design are presented elsewhere (23).
The WMH interviews assessed prevalence and a wide range of predictors and consequences of numerous anxiety, mood, disruptive behavior, and substance disorders (24). The full text of the interview schedule is available at www.hcp.med.harvard.edu/wmh. The following section reviews only the measures considered in the current report.
The WMH interview schedule was developed in English and translated into other languages using a standardized WHO translation, back-translation, and harmonization protocol described elsewhere (25). Consistent interviewer training and quality control monitoring procedures were used in all surveys to facilitate cross-national comparison (26).
Interviews assessed lifetime exposure to 27 traumatic events, including 7 related to war and sectarian violence (e.g., combatant, civilian in a war zone), 5 types of physical assault (e.g., mugged), 3 types of sexual assault, 6 types of trauma involving threats to physical integrity excluding violence (e.g., life-threatening accidents), traumatic death of a loved one, and 5 types of trauma involving threats to others (e.g., life-threatening illness-injury of loved one). Respondents were asked to report lifetime exposure to each trauma on a hard copy list and to check off each endorsed event for future reference. Two additional open-ended questions asked about 1) any other traumatic event not included on the list and 2) traumatic events respondents did not wish to describe concretely. Positive responses were followed by probes to assess the respondent’s age when each trauma first occurred.
Mental disorders were assessed with the WHO Composite International Diagnostic Interview (CIDI) (27), a fully structured interview designed to generate diagnoses of common DSM-IV and ICD-10 mental disorders. DSM-IV criteria, including organic exclusions and diagnostic hierarchy rules, are used here. In addition to PTSD, we consider five anxiety disorders (separation anxiety disorder, panic disorder and/or agoraphobia, generalized anxiety disorder, specific phobia, and social phobia), two mood disorders (major depressive disorder/dysthymia and bipolar disorder), four disruptive behavior disorders (attention-deficit/hyperactivity disorder, oppositional-defiant disorder, conduct disorder, and intermittent explosive disorder), and two substance disorders (alcohol and drug abuse with/without dependence). Age-of-onset (AOO) of each disorder was assessed using special probing techniques shown experimentally to improve recall accuracy (28). Individual-level AOO reports of PTSD and comorbid disorders were compared to define temporally primary comorbid disorders to predict dissociation in 12-month PTSD.
As detailed elsewhere (29), generally good concordance was found between diagnoses based on CIDI and blinded Structured Clinical Interview for DSM-IV (30) clinical reappraisal interviews. Concordance for PTSD was in the moderate range (31), with κ of .49 and area under the receiver operating characteristic curve of .69. The two components of area under the receiver operating characteristic curve, sensitivity and specificity, were 38.3 and 99.1, respectively, resulting in a positive likelihood ratio of 42, which is well above the 10 threshold typically used to define screening scale diagnoses as definitive (32). Consistent with the high positive likelihood ratio, positive predictive value (the proportion of CIDI cases confirmed by the Structured Clinical Interview for DSM-IV) of DSM-IV/CIDI PTSD was 86.1%, suggesting that the vast majority CIDI cases would independently be judged to have PTSD by trained clinicians.
Posttraumatic stress disorder was assessed twice in the CIDI: once for symptoms associated with the respondent’s self-selected worst lifetime trauma and a second time for symptoms associated with one other lifetime trauma selected using a random number generator from the respondent’s lifetime traumas. Occurrence of the 17 DSM-IV Criterion B–D PTSD symptoms was assessed for the month after each trauma when the respondent experienced the largest number of symptoms. (Respondents who reported only one lifetime trauma were, of course, assessed only once.) Respondents who reported any lifetime Criterion B–D symptoms of PTSD associated with each trauma were then asked if they had three or more such symptoms in the 12 months before interview associated with any lifetime trauma. Respondents who answered affirmatively were then evaluated for 12-month PTSD and asked which lifetime events caused these 12-month symptoms. Twelve-month PTSD was defined as meeting full lifetime DSM-IV/CIDI criteria and continuing to have at least some symptoms in the 12 months before interview.
The draft DSM-5 criteria define the dissociative subtype of PTSD as the subset of cases experiencing persistent or recurrent depersonalization or derealization (http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=165). The WMH interview schedule included a section on 30-day prevalence of nonspecific psychological distress that contained two questions on depersonalization (the experience of feeling as though they are standing next to themselves or watching themselves do something and they actually see themselves as if they were looking at another person; and the experience of feeling that their body does not seem to belong to them) and one on derealization (the experience of feeling that other people, objects, and the world around them are not real) from the Dissociative Experiences Scale (33). We defined respondents with 12-month DSM-IV/CIDI PTSD as having an approximation of the dissociative subtype if they reported either often or sometimes (on a four-category response scale that also included the categories rarely and never) having one or more of these three experiences. Cronbach’s α for a scale of these items was .64.
In addition to the variables described above, we examined four potential correlates of dissociation in 12-month PTSD: prior (to the onset of PTSD) trauma history, childhood adversities; current impairments due to PTSD, and recent treatment.
Prior trauma history was assessed by calculating the number of lifetime traumas the respondent reported experiencing at an earlier age than age of exposure to the trauma implicated in their current PTSD.
Childhood adversities (CAs) were assessed with 12 measures, some overlapping with the traumas implicated in the PTSD, that included three types of interpersonal loss (parental death, parental divorce, and other parent-caregiver loss), four types of parental maladjustment (mental illness, substance abuse, criminality, and family violence), four types of maltreatment (physical, sexual, and emotional abuse and neglect), and family economic adversity. Physical and emotional abuse were assessed with a modified version of the Conflict Tactics Scale (34), sexual abuse with questions from the CIDI trauma section, and neglect with questions developed by child welfare researchers on frequency of lacking adequate food, clothing, and medical care; inadequate supervision; and being required to do age-inappropriate chores (35). Parental criminality was assessed with questions about perpetration, arrest, and incarceration (36). Parental mental illness (major depression, generalized anxiety disorder, panic disorder, and suicide attempt) and substance abuse were assessed with the Family History Research Diagnostic Criteria Interview (37) and its extensions (38). Family violence was assessed with the modified Conflict Tactics Scale. Economic adversity was assessed with questions about how often the respondent’s family of origin lacked basic necessities of living. The distributions and structure among the CAs are reported elsewhere (39,40), where we show that the parental maladjustment and respondent maltreatment CAs cluster together into what we have referred to as a pattern of maladaptive family functioning.
Impairment due to PTSD was assessed with separate questions about suicidality and role functioning. Suicidality was assessed with the CIDI suicidal behavior module (41), which asked about 12-month occurrence of suicide ideation, plans, and attempts. Role functioning was assessed with a modified version of the Sheehan Disability Scale (SDS) (42), which asked respondents to rate how much their PTSD interfered with each of four role domains (home management, ability to work, social life, and close relationships) using a 0 to 10 response scale of None (0), Mild (1–3), Moderate (4–6), Severe (7–9), and Very Severe (10) interference. A global SDS score was created by assigning each respondent the highest SDS domain score across the four domains.
Recent treatment was assessed with questions administered to all part II WMH respondents about treatment in the past 12 months for problems with their emotions, nerves, or use of alcohol or drugs in each of four sectors: specialty (psychiatrist, psychologist, or other health care provider in a mental health specialty setting), general medical (nonpsychiatrist health care provider not in a mental health specialty setting), human services (religious-spiritual advisor, social worker, or counselor not in the mental health specialty setting), and complementary-alternative medical (any other healer, internet support group, self-help group). In addition, respondents with 12-month PTSD were asked if they saw any professional in the past 12 months specifically for their PTSD.
Cross-tabulations were used to estimate prevalence of dissociation among respondents with 12-month PTSD and the association between trauma type and dissociation among respondents with 12-month PTSD. Logistic regression analysis (43) was used to examine correlates of dissociation among respondents with 12-month PTSD. The logistic regression coefficients and their standard errors were exponentiated and are reported here as odds ratios (ORs) with 95% confidence intervals. To adjust for the weighting-clustering of WMH data, standard errors were estimated using the Taylor series method (44) implemented in the SUDAAN software system (Research Triangle International, Research Triangle Park, North Carolina) (45). Multivariate significance was evaluated with Wald χ2 tests based on design-corrected coefficient variance-covariance matrices. Statistical significance was consistently evaluated using .05 level two-sided tests.
Twelve-month prevalence (standard error) of DSM-IV/CIDI PTSD in the total sample is 1.9% (.1), with 14.4% (1.3) of these cases estimated to have the dissociative subtype (Table 1). The latter proportion does not differ significantly across the seven broad types of trauma assessed in the surveys (χ26 = 8.5, p = .20). This compares with a 2.8% (.1) prevalence of these dissociative symptoms in the remainder of the sample.
Among respondents with 12-month DSM-IV/CIDI PTSD, presence of dissociation was significantly and positively associated with number of re-experiencing symptoms (Criteria B1–B5) but not with numbers of avoidance (Criteria C1–C3), emotional numbing (Criteria C4–C7), or hyperarousal (Criteria D1–D5) symptoms (Table 2). More detailed analyses found that Criterion B3 (flashbacks; OR = 2.3, 95% confidence interval = 1.3–4.2) accounts for the association of re-experiencing with dissociation, that the only other individual symptom significantly associated with dissociation is Criterion C3 (psychogenic amnesia; OR = 1.6, 95% confidence interval = 1.0–2.6), and that no significant differences exist by country income level in the associations of symptom with dissociation (χ24 = .4, p = .82). (Detailed results of these and other analyses not reported in tables are available on request.)
Controlling for type of trauma implicated in the PTSD, odds of dissociation among respondents with 12-month PTSD are significantly elevated among men (OR = 1.7), respondents whose PTSD started in childhood (2.8–4.1), and respondents who experienced prior traumas (2.0–4.7) (Table 3). Number of years since onset of PTSD and country income level, in comparison, are not significantly associated with dissociation. These patterns are largely unchanged with additional controls for numbers of symptoms of re-experiencing, avoidance, emotional numbing, and hyperarousal. More detailed analyses found a significant interaction of country income level with AOO of PTSD in predicting dissociation (χ23 = 3.4, p = .022). This interaction indicates that the elevated OR of dissociation associated with early AOO is confined to ages 1 to 12 in high-income countries and extends to ages 1 to 19 in low/middle income countries. None of the other predictors in Table 3 has a significant interaction with country income level.
Almost all CAs considered in the WMH surveys are associated with elevated odds of dissociation among respondents with 12-month PTSD in bivariate models (OR = 1.3–2.2). Four of these associations are significant (parental mental illness and substance disorder, family violence, and parental divorce) (Table 4). These associations all attenuate in a multivariate additive model. An alternative model in which numbers rather than types of CAs are used as predictors finds a significant dose-response relationship between numbers of maladaptive family functioning CAs and dissociation. The ORs of individual CAs all become nonsignificant when controls are introduced for numbers of CAs. The ORs in the numbers of CAs model remain significant when additional controls are introduced for numbers of symptoms of re-experiencing, avoidance, emotional numbing, and hyperarousal. More detailed analyses found no significant differences by country income level in the associations of CAs with dissociation.
All but 2 of the 13 temporally prior (to the onset of PTSD) lifetime comorbid DSM-IV/CIDI disorders considered here are associated with elevated odds of dissociation among respondents with 12-month PTSD in bivariate models (OR = 1.4–3.3). Six of these associations are significant (bipolar disorder, separation anxiety disorder, panic/agoraphobia, generalized anxiety disorder, specific phobia, and oppositional-defiant disorder) (Table 5). An alternative model in which numbers rather than types of comorbid disorders are used as predictors finds that high comorbidity (i.e., four or more comorbid disorders) is associated with especially elevated odds of dissociation (10.0). The numbers of disorders coefficients become nonsignificant, while the coefficients associated with separation anxiety disorder and specific phobia remain significant (3.0–3.6) in a model that includes both types and numbers of comorbid disorders as predictors. The ORs in the most parsimonious model (i.e., the model using only numbers of disorders as predictors) are largely unchanged when additional controls are introduced for numbers of symptoms of re-experiencing, avoidance, emotional numbing, and hyperarousal. More detailed analyses found no significant differences by country income level in these associations of disorders with dissociation.
Significantly higher proportions of respondents with than without dissociation reported severe 12-month role impairments due to their PTSD (Table 6). Odds ratios in bivariate models across the four SDS scales (1.8–3.6) are consistently significant and remain elevated (1.8–3.6) in models that control for PTSD symptom counts. Dissociation is also associated with significantly elevated odds of 12-month suicidality (3.4–6.1). These ORs remain elevated (3.2–5.0) in models that control for PTSD symptom counts. More detailed analyses found no significant interactions between country income level and dissociation in predicting either impairments or suicidality (χ21 = .1–1.9, p = .17–.79).
The rate of 12-month treatment for any emotional problem is insignificantly higher among respondents with PTSD in the presence versus absence of dissociative symptoms and remains unchanged when we control for PTSD symptom counts. The rate of 12-month treatment specifically for PTSD is not meaningfully higher in the presence versus absence of dissociative symptoms despite the higher rates of severe role impairment and suicidality associated with dissociation. More detailed analyses found no significant interactions between country income level and dissociation in predicting either type of treatment (χ21 = 1.0–2.0, p = .16–.31).
These results have to be interpreted in the context of several study limitations. The number of respondents with 12-month PTSD was too small for country-specific analyses. Posttraumatic stress disorder was assessed with a fully structured lay-administered interview rather than a clinical interview, introducing the possibility of conceptual confounding. This possibility increases due to the fact that the dissociation items were chosen post hoc rather than developed specifically to operationalize the proposed DSM-5 criteria. This limited assessment, the potential overlap of dissociative symptoms with a range of quite different experiences (e.g., symptoms of mood, anxiety, and psychotic disorders (46–48), and the fact that dissociative symptoms were assessed in a separate part of the interview and for a different time frame (past 30 days) should all lead to caution in interpreting results. Our use of a simple yes-no dichotomy to differentiate cases of PTSD with and without dissociative symptoms, furthermore, while consistent with the proposed DSM-5 formulation, can also be considered a limitation in that it failed to consider either the more fine-grained differentiations among dissociative symptoms called for in some studies (49,50) or the possibility that dissociation might be characterized more accurately as being on a continuum rather than as being associated with a distinct dichotomous subtype of PTSD (51,52). These refinements could not be investigated due to the small number of dissociative symptoms assessed.
Bearing these limitations in mind, the results presented here provide the first cross-national population-level epidemiologic data on the distribution and correlates of dissociative symptoms in PTSD. A number of key findings are noteworthy. The most fundamental of these is that we found 14.4% of PTSD cases in the community to meet criteria for the dissociative subtype, a proportion that does not differ significantly across the diverse set of countries considered here. This demonstrates clearly that the dissociative subtype is not confined to developed countries. This proportion is within the range found in previous studies (5–7,15,16).
Only one of our findings is in some sense inconsistent with previous evidence regarding correlates of dissociation in PTSD: that the proportion of cases meeting criteria for a dissociative subtype is significantly higher among male subjects than female subjects. Previous clinical studies either found dissociation more common among women than men (5,7,17) or no gender difference (15). Yet, the elevated OR of dissociation among male subjects versus female subjects is quite stable in the WMH data in that it is comparable in high-income and low/middle income countries. Given this consistency, the association deserves further investigation to determine the relevant psychological and biological mechanisms involved.
An especially intriguing set of WMH findings is that dissociation among respondents with PTSD is associated with childhood onset, exposure to prior traumatic events (and especially to a high number [5+] of prior traumatic events), and childhood adversities. When considered in conjunction with the finding that dissociation is not related to trauma type, this implies that early age of exposure and repeated exposure are more critical than the content of exposure in promoting dissociative symptoms among people with PTSD. Clinical research is consistent with the finding that dissociative symptoms in PTSD can be found across a wide range of trauma types (9,53). A number of studies have also found that dissociation might be more common in early-onset PTSD associated with exposure to a complicated series of traumas (e.g., [15,54,55]). This pattern is consistent with discussions in clinical studies about complex PTSD and Disorders of Stress Not Otherwise Specified (56,57). However, these formulations suggest that such individuals also exhibit behavioral difficulties (such as impulsivity, aggression, sexual acting out, alcohol/drug misuse, and self-destructive actions), emotional difficulties (such as affective lability, rage, depression, and panic), cognitive difficulties (such as dissociation and pathological changes in personal identity), interpersonal difficulties, somatization, and in the most recent formulation, deficits in regulating emotional distress (58). These broader sets of symptoms were not assessed in the WMH surveys, leaving it for future investigators to determine the relationship between the dissociative subtype and complex PTSD.
The WMH findings that dissociation is associated with elevated PTSD symptom counts, high role impairment, and suicidality are consistent with clinical evidence that dissociation is related to severity of PTSD (7,11,59). It is striking in light of this fact that we failed to find evidence that respondents whose PTSD featured dissociation were more likely than those without dissociation to obtain treatment for their PTSD. This finding might indicate that dissociation undermines treatment seeking for PTSD, perhaps highlighting the need for differential screening and treatment strategies for people whose PTSD includes dissociative symptoms (4,60).
These results help to characterize the proposed dissociative subtype of PTSD in community samples. We document clearly that dissociation exists in a meaningful and roughly equal proportion of PTSD cases throughout a diverse set of countries. We find that the proposed dissociative subtype has value not only in that it distinguishes a meaningful proportion of PTSD cases but also that these cases have a distinct clinically meaningful set of predictors and consequences that are roughly equivalent across countries. And we find that this subtype is associated with a particularly impairing form of PTSD. These results raise the possibility that dissociation might be a marker of a complex form of PTSD characterized not only by early onset and exposure to multiple childhood traumas-adversities but also by multiple comorbidities and other clinical features not assessed in the WMH surveys. While evaluation of this possibility goes beyond the scope of the current report, the results presented here suggest that it deserves future empirical investigation.
The research reported here was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. These activities were supported by the United States National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, R01-MH092526, and R01-DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, the Eli Lilly & Company Foundation, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Shire Pharmaceuticals. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders is supported by the Ministry of Health and the National Center for Public Health Protection. The Beijing, Peoples Republic of China World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123), the Piedmont Region (Italy), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from Glaxo-SmithKline. The World Mental Health Japan Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation) is supported by the Lebanese Ministry of Public Health, the World Health Organization (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), anonymous private donations to the Institute for Development, Research, Advocacy & Applied Care, Lebanon, and unrestricted Grants from Astra Zeneca, Eli Lilly, GlaxoSmithKline, Hikma Pharm, Janssen Cilag, MSD, Novartis, Pfizer, Sanofi Aventis, and Servier. The Mexican National Comorbidity Survey is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology and Ministry of Health. The Romania WMH study projects “Policies in Mental Health Area” and “National Study regarding Mental Health and Services Use” were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, Statistics Contract 70, Cheyenne Services Societate cu Responsabilitate Limitata, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania Societate cu Responsabilitate Limitata. The US National Comorbidity Survey Replication is supported by the National Institute of Mental Health (U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (Grant 044708), and the John W. Alden Trust.
These surveys were carried out in conjunction with the World Health Organization WMH Survey Initiative.
We thank the WMH staff for assistance with instrumentation, fieldwork, and data analysis. A complete list of WMH publications can be found at www.hcp.med.harvard.edu/wmh.
Dr. Stein has received research grants and/or consultancy honoraria from Abbott, Astra Zeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. Dr. Demyttenaere has served on advisory boards and speaker bureaus for and has research grants from AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Takeda, and Servier. Dr. Haro has been a consultant for AstraZeneca, Eli Lilly and Co., and Lundbeck. Dr. Kessler has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly & Company, GlaxoSmithKline Inc., HealthCore Inc., Health Dialog, Integrated Benefits Institute, John Snow Inc., Kaiser Permanente, Matria Inc., Mensante, Merck & Co Inc., Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc., Primary Care Network, Research Triangle Institute, Sanofi-Aventis Groupe, Shire US Inc., SRA International Inc., Takeda Global Research & Development, Transcept Pharmaceuticals Inc., and Wyeth-Ayerst; has served on advisory boards for Appliance Computing II, Eli Lilly & Company, Mindsite, Ortho-McNeil Janssen Scientific Affairs, Plus One Health Management, and Wyeth-Ayerst; and has had research support for his epidemiological studies from Analysis Group Inc., Bristol-Myers Squibb, Eli Lilly & Company, EPI-Q, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs., Pfizer Inc., Sanofi-Aventis Groupe, and Shire US, Inc. Drs. Koenen and Friedman, Mr. Hill, and Drs. McLaughlin, Petukhova, Ruscio, Shahly, Spiegel, Borges, Bunting, Caldas-de-Almeida, de Girolamo, Florescu, Karam, Kovess-Masfety, Lee, Matschinger, Mladenova, Posada-Villa, Tachimori, and Viana report no biomedical financial interests or potential conflicts of interest.
The views and opinions expressed in this article are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or US government.